EUR-Lex Access to European Union law
This document is an excerpt from the EUR-Lex website
Document 92014E004776
Written question E-004776/14 Erik Bánki (PPE), Csaba Sógor (PPE), Petru Constantin Luhan (PPE), Teresa Riera Madurell (S&D), Oreste Rossi (PPE), Carl Schlyter (Verts/ALE), Nikos Chrysogelos (Verts/ALE), Michèle Rivasi (Verts/ALE), Monika Panayotova (PPE) and Kathleen Van Brempt (S&D) to the Commission. Inflammatory bowel disease
Written question E-004776/14 Erik Bánki (PPE), Csaba Sógor (PPE), Petru Constantin Luhan (PPE), Teresa Riera Madurell (S&D), Oreste Rossi (PPE), Carl Schlyter (Verts/ALE), Nikos Chrysogelos (Verts/ALE), Michèle Rivasi (Verts/ALE), Monika Panayotova (PPE) and Kathleen Van Brempt (S&D) to the Commission. Inflammatory bowel disease
Written question E-004776/14 Erik Bánki (PPE), Csaba Sógor (PPE), Petru Constantin Luhan (PPE), Teresa Riera Madurell (S&D), Oreste Rossi (PPE), Carl Schlyter (Verts/ALE), Nikos Chrysogelos (Verts/ALE), Michèle Rivasi (Verts/ALE), Monika Panayotova (PPE) and Kathleen Van Brempt (S&D) to the Commission. Inflammatory bowel disease
SL C 416, 20.11.2014, p. 84–102
(BG, ES, EL, EN, FR, IT, HU, NL, RO, SV)